Fig. 7
In vivo therapeutic efficacy of FeOOH&mSiO2 Janus nanoparticles conducted with 4T1-tumor-bearing mice. (A) Schematic illustration of tumor model establishment and treatment process. The nanocomposite was administered intravenously at 0, 2nd, 5th, 9th, 12th, 16th, 19th and 21st days. (B) Eventual tumor growth rate of 4T1 tumor-bearing mice treated with saline (control group), FMS, DOX and FMS-DOX calculated with dissected tumor weight (Normalized with the group treated with FMS-DOX). Data are expressed as mean standard ± errors (n = 3). (C) Tumor volume growth curves of 4T1 tumor-bearing mice treated with saline (control group), FMS, DOX and FMS-DOX. Data are expressed as mean standard ± errors (n = 3). (D) Body weights of tumor-bearing mice during treatments. Data are expressed as mean standard ± errors (n = 3). (E) H&E staining of tumor tissues harvested from corresponding mice after 21 days of treatments. Scale bar: 50 μm